Oppenheimer Cuts Teladoc Health (NYSE:TDOC) Price Target to $21.00

Teladoc Health (NYSE:TDOC) had its price target decreased by Oppenheimer from $26.00 to $21.00 in a research report report published on Friday, Benzinga reports. Oppenheimer currently has an outperform rating on the health services provider’s stock.

Other equities research analysts have also recently issued reports about the company. Citigroup cut their target price on Teladoc Health from $21.00 to $19.00 and set a neutral rating on the stock in a research note on Wednesday, February 21st. Evercore ISI cut their price objective on shares of Teladoc Health from $15.00 to $14.00 and set an in-line rating on the stock in a research note on Friday. Needham & Company LLC restated a hold rating on shares of Teladoc Health in a research note on Friday. Canaccord Genuity Group cut their price objective on shares of Teladoc Health from $28.00 to $25.00 and set a buy rating on the stock in a research note on Friday. Finally, DA Davidson cut their price objective on shares of Teladoc Health from $22.00 to $18.00 and set a neutral rating on the stock in a research note on Wednesday, February 21st. Eleven analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of Hold and a consensus price target of $19.00.

Teladoc Health Stock Performance

TDOC stock opened at $13.01 on Friday. The company has a debt-to-equity ratio of 0.66, a quick ratio of 3.47 and a current ratio of 3.54. The stock has a market capitalization of $2.20 billion, a price-to-earnings ratio of -9.23 and a beta of 0.94. Teladoc Health has a 1 year low of $12.65 and a 1 year high of $30.41. The stock’s fifty day moving average is $14.85 and its two-hundred day moving average is $17.71.

Teladoc Health (NYSE:TDOC) last posted its earnings results on Thursday, April 25th. The health services provider reported ($0.49) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.47) by ($0.02). The company had revenue of $646.13 million during the quarter, compared to the consensus estimate of $637.31 million. Teladoc Health had a negative net margin of 8.90% and a negative return on equity of 10.11%. The business’s quarterly revenue was up 2.7% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($0.37) earnings per share. On average, research analysts predict that Teladoc Health will post -1.06 EPS for the current year.

Insiders Place Their Bets

In other Teladoc Health news, EVP Andrew Turitz sold 6,190 shares of the business’s stock in a transaction dated Monday, March 4th. The shares were sold at an average price of $14.52, for a total value of $89,878.80. Following the sale, the executive vice president now directly owns 39,429 shares in the company, valued at $572,509.08. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. In related news, EVP Andrew Turitz sold 6,190 shares of Teladoc Health stock in a transaction dated Monday, March 4th. The stock was sold at an average price of $14.52, for a total value of $89,878.80. Following the transaction, the executive vice president now owns 39,429 shares of the company’s stock, valued at approximately $572,509.08. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Daniel Trencher sold 6,780 shares of Teladoc Health stock in a transaction dated Monday, March 4th. The stock was sold at an average price of $14.52, for a total value of $98,445.60. Following the completion of the transaction, the insider now directly owns 28,192 shares in the company, valued at approximately $409,347.84. The disclosure for this sale can be found here. Over the last three months, insiders have sold 135,441 shares of company stock worth $2,038,251. 1.63% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Teladoc Health

A number of institutional investors have recently bought and sold shares of the stock. Parallel Advisors LLC lifted its position in shares of Teladoc Health by 14.6% in the fourth quarter. Parallel Advisors LLC now owns 4,038 shares of the health services provider’s stock worth $87,000 after purchasing an additional 515 shares in the last quarter. M&T Bank Corp increased its stake in Teladoc Health by 5.5% in the 4th quarter. M&T Bank Corp now owns 11,152 shares of the health services provider’s stock valued at $241,000 after buying an additional 584 shares during the period. Van ECK Associates Corp lifted its position in Teladoc Health by 20.3% in the 4th quarter. Van ECK Associates Corp now owns 3,589 shares of the health services provider’s stock worth $77,000 after buying an additional 606 shares in the last quarter. Arizona State Retirement System boosted its stake in shares of Teladoc Health by 1.4% during the 3rd quarter. Arizona State Retirement System now owns 46,602 shares of the health services provider’s stock valued at $866,000 after buying an additional 650 shares during the period. Finally, Victory Capital Management Inc. grew its holdings in shares of Teladoc Health by 4.3% during the 3rd quarter. Victory Capital Management Inc. now owns 17,946 shares of the health services provider’s stock valued at $334,000 after acquiring an additional 748 shares in the last quarter. Hedge funds and other institutional investors own 76.82% of the company’s stock.

About Teladoc Health

Teladoc Health, Inc provides virtual healthcare services worldwide. The company operates through Teladoc Health Integrated Care and BetterHelp segments. The Integrated Care segment offers virtual medical services, including general medical, expert medical, specialty medical, chronic condition management, and mental health, as well as enabling technologies and enterprise telehealth solutions for hospitals and health systems.